Skip to content

VDV Pharma

Active Private limited companyfounded 2020active for 6 yearsHelmetsesteenweg 373, 1030 SchaerbeekKBO/BCE: BE 0750.740.804

Annual accounts 2025

full format, filed on 17-11-2025, 75 days before the deadline
€281,698
▼ 6.6%
€109,491
▼ 32.5%
€66,371
▼ 37.7%
-€392,026
▲ €48,702
13.3%
▲ 5.0 percentage points
0.47
▼ 0.02

Turnover is estimated at about €970,000, probably between €760,000 and €1.3m.

Balance sheet

balance sheet total €1.5m on 30-06-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

13.3%

Higher than 25% of the 6,427 companies filing full accounts in retail trade (NACE 47) in 2024.

0.47

Higher than 7% of the 6,379 companies filing full accounts in retail trade (NACE 47) in 2024.

4.4%

Higher than 54% of the 6,401 companies filing full accounts in retail trade (NACE 47) in 2024.

VDV Pharma Middle half of the sector 80% of the sector Full accounts in retail trade (NACE 47)

Staff

€63,619

Staff costs divided by the average number of full-time equivalents.

+1 employee

employees who joined employees who left

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420232022202111 months
182,818231,503197,001195,53451,327
139,698175,912149,584155,19641,176
41,8046,5931.1m2,123327,382
-77,88276,612-40,93190,664-
-392,026-440,728-324,562154,88436,058
13.3%8.3%15.6%29.4%9.9%
0.470.490.502.191.44
0.310.360.361.630.80
6.5411.045.422.409.09
33.0%78.9%34.0%74.5%40.3%
4.4%6.6%5.3%21.9%4.0%
7.438.917.2829.79-

EBIT margin not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420232022202111 months
Balance sheet: assets
20/58 1.5m1.6m1.6m558,270422,453
20 8210412614816
21/28 1.2m1.2m1.3m272,505303,259
21 303,750353,250402,750247,500277,500
22/27 360,833342,653357,15324,85525,609
22 313,820318,560330,845--
23 17,84520,90420,66022,47225,137
24 3,0273,1895,6482,383472
25 26,140----
28 508,336508,336506,840150150
29/58 345,230421,098328,810285,151118,378
3 118,891106,77090,38673,23252,631
30/36 118,891106,77090,38673,23252,631
40/41 91,277126,295158,574106,30051,133
40 79,77788,679111,63673,89651,101
41 11,50037,61646,93832,40332
50/53 68,88445,00015,000--
54/58 62,510140,39263,780104,71114,047
490/1 3,6692,6411,070908567
Balance sheet: equity and liabilities
10/49 1.5m1.6m1.6m558,270422,453
10/15 201,427135,056248,442163,97641,859
10/11 25,00025,00025,00025,00025,000
14 176,427110,056223,442138,97616,859
17/49 1.3m1.5m1.3m394,294380,594
17 579,474627,479693,047264,027298,274
170/4 579,474627,479693,047264,027298,274
42/48 737,257861,826653,371130,26782,320
42 73,64667,07663,98534,24733,744
43 30,00030,00030,00020,000-
430/8 30,00030,00030,00020,000-
44 50,49150,115281,18843,26235,350
440/4 50,49150,115281,18843,26235,350
45 19,34915,79715,34632,75910,535
450/3 3274,1103,90119,9715,645
454/9 19,02211,68811,44612,7874,889
47/48 563,771698,838262,85302,692
492/3 01,1871,105--
Income statement
9900 281,698301,615265,189272,343108,592
62 95,42964,77366,64376,80956,915
630 73,32769,29865,11933,07924,317
640/8 3,4515,3391,5450350
9901 109,491162,205131,883162,45527,010
75/76B 01,9572,419932-
75 01,9572,419932-
65/66B 24,59225,99027,0526,5656,291
65 24,59225,99027,0526,5656,291
9903 84,899138,172107,249156,82220,719
67/77 18,52831,55722,78434,7053,860
9904 66,371106,61484,465122,11716,859
9905 66,371106,61484,465122,11716,859
Appropriation of the result
9906 176,427330,056223,442138,97616,859
14P 110,056223,442138,97616,859-
694/7 0220,000---
694 0220,000---
Social balance sheet
9087 1.50.90.920.9
Hours worked1013 2,5181,4711,5002,0241,734
Document PDFPDFPDFPDFPDF

The full notes are in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 17-11-2025.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
30-06-2025 full format 17-11-2025 2025-00567119 PDF
30-06-2024 full format 07-01-2025 2025-00000428 PDF
30-06-2023 full format 23-01-2024 2024-00004627 PDF
30-06-2022 micro format 12-12-2022 2022-20535287 PDF
30-06-2021 micro format 04-01-2022 2022-00100488 PDF

Social balance sheet

Item30-06-202530-06-202430-06-202330-06-2022
Employees at the balance-sheet date2112
full-time1000
part-time1112
in full-time equivalents1.80.80.81.1
1.50.90.91.1
On a permanent contract2112
Joined2-0-
Left1-1-

Source: social balance sheet in the 2022 to 2025 annual accounts

Securities and guarantees

on own assets and for others
Item30-06-202530-06-202430-06-202330-06-2022
Debts secured on the company's own assets€653,120€694,556€757,031-
Mortgages, amount registered€300,000€300,000€330,000-
Carrying value of the mortgaged assets€313,821€328,976€333,103-
€603,932€603,932€603,932€357,000

Source: notes to the 2022 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item30-06-202530-06-202430-06-202330-06-2022
Tangible fixed assets€41,804€5,096€357,465€2,123
Intangible fixed assets--€195,000-
Financial fixed assets-€1,497€506,690-
€73,327€69,298€65,119€33,079

Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)

Insights on VDV Pharma

The operating result for 2025 is 32% lower than in 2024 and the lowest since 2022.

Debt's share of the balance-sheet total falls from 91.7% to 86.7%. Equity is higher and debt is lower.

Large changes and their cause
  • 2022 Compared with 2021, the net result rose by 624%. The previous financial year ran 11 months, this one 12.

Next steps